Abzu vs Invitris

<p>Abzu is a biotechnology software platform that leverages artificial intelligence to develop advanced RNA therapies such as siRNAs, ASOs, and anti-miRs for major medical needs. It integrates deep RNA biology knowledge with AI-driven design and drug development expertise, enabling you to explore and prioritize vast RNA sequence variants computationally. This reduces experimental costs, shortens candidate selection time, and improves overall drug design efficiency.</p> <p>The platform also supports targeted RNA delivery by developing programmable aptamers for cell-specific uptake, creating a modular system for precision beyond traditional liver-focused delivery. Abzu serves biotech researchers and pharmaceutical teams aiming to innovate RNA drug development, offering case studies and AI models that enhance therapeutic design safety and efficacy. While currently fundraising, Abzu emphasizes explainable AI to boost pharma trust and streamline workflows.</p>

<p>Invitris is a cutting-edge biotechnology platform specializing in cell-free protein synthesis. It enables you to design, express, and scale complex proteins faster and with greater flexibility than traditional cell-based methods. With systems optimized for microbial and mammalian protein production, Invitris supports rapid workflows and high-throughput screening, letting you accelerate research and development in biopharmaceuticals, industrial biotechnology, agriculture, and antimicrobial resistance.</p> <p>It provides tools for rapid protein engineering, integrating computational design with high-throughput screening, and supports seamless scalability from picoliter reactions to large-scale manufacturing. Invitris also offers co-development and licensing partnerships to help you bring innovative biotech solutions to market efficiently. The platform is designed to streamline your protein production process with scalable, tunable, and efficient technologies tailored to a variety of life science applications.</p>